Gene Expression, Immune Response and Trials - Clinical Research Informer

Gene Expression

Immune Response

Trials

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials

Clinical Trials Clinical Trials Vaccination Vaccine

Gene Therapy and Pharmacokinetics

Camargo

JULY 27, 2021

Additionally, gene editing allows us either to remove or to modify harmful genes. While most gene therapy clinical studies are ongoing, a number of products are in advanced clinical development, and several are approved by FDA. Gene Expression Considerations.

Gene Therapy

Gene Therapy Gene Gene Editing Genetics

Join 32,000+

Insiders

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

World Mental Health Day 2023: Drug discovery breakthroughs

Drug Discovery World

OCTOBER 10, 2023

Read more: Preclinical study proves antidepressant effects of drug Psychedelic-based drug options Later the same month, Cybin announced it had completed dosing in Cohort 5 of a Phase II trial evaluating CYB003, an investigational proprietary deuterated analog of psilocybin for the potential treatment of major depressive disorder (MDD).

Drugs

Drugs Gene Expression Gene Immune Response

Cash round sets up trial of InteRNA’s microRNA for cancer

pharmaphorum

FEBRUARY 9, 2021

million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours. The start of dosing in the phase 1/1b trial of the drug has been delayed by the COVID-19 pandemic, but recruitment of the target 80 participants with advanced solid tumours is reported to be ongoing.

Trials

Trials Gene Silencing RNA Gene Expression

Personalised mRNA cancer vaccine prolongs survival in melanoma

Drug Discovery World

APRIL 16, 2023

The clinical benefit was observed regardless of the tumour mutational burden (TMB) status, according to results from the Phase IIb KEYNOTE-942 clinical trial presented at the AACR Annual Meeting 2023, held April 14-19. In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response.

Vaccination

Vaccination Vaccine Immune Response Gene Expression

Zynteglo halt re-ignites viral vector safety concerns; analysts

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.

Gene Therapy

Gene Therapy Gene Gene Sequencing Gene Expression

How transcriptomics is driving drug discovery

Drug Discovery World

FEBRUARY 13, 2023

Diseases ranging from cancer to viral immune response, from cardiovascular to reproductive health, and from metabolic to nervous systems all have the potential to benefit from in-depth transcriptomics. DDW: Can RNA profiling be used past the point of early development to monitor how drugs perform within clinical trials?

RNA

RNA Drugs Gene Expression Gene

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Pharma Marketing Network

DECEMBER 21, 2020

those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. greater safety, transient and reversible effect on gene expression).

Genetics

Genetics Medicine Gene Therapy Marketing

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

The Pharma Data

NOVEMBER 9, 2020

Trial Also Met the Primary Endpoint in Patients With Low Levels of Eosinophils. In the subgroup of patients with baseline eosinophil counts less than 300 cells per microliter, the trial met the primary endpoint with tezepelumab demonstrating a statistically significant and clinically meaningful reduction in AAER.

Trials

Trials Production Sales Manufacturing

How big data analytics can make personalised care a reality

Drug Discovery World

FEBRUARY 6, 2023

It’s a rapid growth area for clinical trials in the next few years as we seek to understand the underlying biology behind many of the targets and diseases we study. For example, we recently collaborated with two sequencing laboratories to determine optimal parameters for RNA-Sequencing (RNA-Seq) in the context of a vaccine clinical trial.

Big Data

Big Data RNA Bioinformatics Vaccination

What spatial biology can tell us about disease and drug discovery

Drug Discovery World

OCTOBER 17, 2023

Analysing spatial changes during disease progression or treatment response is key to fully understand pathologies. RA: With spatial biology being cross-disciplinary – in that it uses techniques in both gene expression analysis and immunofluorescence – is expertise in the field limited?

Gene Expression

Gene Expression Drugs Protein Gene

Tezepelumab granted Priority Review by U.S. FDA

The Pharma Data

JULY 8, 2021

8) There were no clinically meaningful differences in safety results between the tezepelumab and placebo groups in the NAVIGATOR trial.(8) 8) There were no clinically meaningful differences in safety results between the tezepelumab and placebo groups in the NAVIGATOR trial.(8)

Allergies

Allergies Trials In-Vivo Medicine

Clinical Catch-Up: December 21-25 | BioSpace

The Pharma Data

DECEMBER 27, 2020

Even with the holidays among us, there were a number of clinical trial announcements. Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. Here’s a look. COVID-19-Related. Non-COVID-19-Related.

Trials

Trials Antibody Gene Therapy Clinical Trials

Delivering on the promise of gene editing

Drug Discovery World

DECEMBER 15, 2022

Now, after nearly 35 years of research and more than a decade of preclinical progress, several different gene editing modalities are being tested in early phase clinical trials. Early phase clinical trials for gene editing therapies. Gene editing challenges and potential solutions.

Gene Editing

Gene Editing Gene In-Vivo Genome

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

Gene Therapy and Pharmacokinetics

Trending Sources

World Mental Health Day 2023: Drug discovery breakthroughs

Cash round sets up trial of InteRNA’s microRNA for cancer

Personalised mRNA cancer vaccine prolongs survival in melanoma

Zynteglo halt re-ignites viral vector safety concerns; analysts

How transcriptomics is driving drug discovery

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

How big data analytics can make personalised care a reality

What spatial biology can tell us about disease and drug discovery

Tezepelumab granted Priority Review by U.S. FDA

Clinical Catch-Up: December 21-25 | BioSpace

Delivering on the promise of gene editing

Stay Connected